Home Featured Page 271

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Mydecine to Report Full Year 2020 Financial Results on May 3,...

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction...

Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief...

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon...

PTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience

MindMed To Commence Trading on Nasdaq

Champignon Brands Announces Revocation of Cease Trade Orders

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin...

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Mydecine to Report Full Year 2020 Financial Results on May 3,...

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction...

Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief...

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon...

PTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience

MindMed To Commence Trading on Nasdaq

Champignon Brands Announces Revocation of Cease Trade Orders

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin...

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY